HHS Secretary Robert F. Kennedy Jr. has stopped federal support for mRNA-based vaccines, including malaria vaccine efforts. Malaria is deadly, causing hundreds of thousands of deaths annually. Research into mRNA malaria vaccines shows promise, with studies suggesting they could significantly… Read More »Malaria mRNA-based vaccines showing promise in preclinical trials
HHS Secretary RFK Jr. has canceled over $500 million in mRNA vaccine funding, jeopardizing future vaccine development amidst ongoing health crises like bird flu. His anti-mRNA stance contradicts scientific evidence, risking delays in vital research. This decision threatens public health… Read More »RFK Jr cancels $500 million funding of mRNA vaccine research
BioNTech’s pancreatic cancer mRNA vaccine candidate, cevumeran, has shown promising results in a phase 1 trial, offering hope in cancer treatment. Individualized to each patient, it enhances immune response post-surgery and may prevent recurrence. A forthcoming phase 2 trial aims… Read More »Pancreatic cancer mRNA vaccine — exciting clinical trial results
The author shares insights from their annual review of the top 10 most-read articles in 2024, primarily focused on vaccines, especially related to COVID and cancer. They highlight three enduring past articles and mention the ongoing interest in COVID-related content.… Read More »The 2024 top 10 (or 13) articles on Skeptical Raptor
Early clinical trials indicate that two norovirus vaccines show promise. Moderna’s mRNA-1403 vaccine demonstrated strong antibody responses and safety in adults, while Vaxart’s oral vaccine showed a reduction in norovirus infections but did not meet its primary endpoint. FDA approval… Read More »Norovirus vaccines are showing promise in clinical trials
BioNTech has announced early promising results for their new lung cancer mRNA vaccine candidate, BNT116. This vaccine works by presenting specific antigens to the immune system, activating immune cells to target cancer cells. Currently in phase 2 trials, it could… Read More »Lung cancer mRNA vaccine shows promising results
The FDA has approved Moderna’s mRNA vaccine for respiratory syncytial virus (RSV) to prevent serious lung infections, especially in vulnerable populations like infants and older adults. Clinical trials show the vaccine is effective and safe, though concerns and skepticism from… Read More »Moderna’s mRNA vaccine for RSV approved by the FDA
The FDA has approved an investigational new drug (IND) application for a novel mRNA therapeutic cancer vaccine, targeting Epstein-Barr virus-positive solid tumors and hematoma in adults. This vaccine, developed by WestGene Biotech, is intended for clinical trials under the name… Read More »Another mRNA vaccine cancer treatment — Epstein-Barr virus
An April 2024 report by the National Academies of Sciences, Engineering, and Medicine (NASEM) refutes any causal link between mRNA COVID vaccines and most severe adverse events. Acknowledging a connection to mild, recoverable myocarditis, it found no evidence of association… Read More »More evidence for the safety of COVID mRNA vaccines
A new personalized mRNA vaccine for pancreatic cancer, cevumeran, has shown promise in a phase 1 trial and is advancing to a larger phase 2 trial. It works by inducing an immune response against specific antigens in each patient’s tumor,… Read More »New mRNA vaccine for pancreatic cancer enters phase 2 trials